Can-Fite BioPharma vs Yarrow Bioscience
CANF and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CANF and YARW compare
Yarrow Bioscience grew revenue faster over the last twelve months (13.8% versus −39.9% for Can-Fite BioPharma).
Can-Fite BioPharma keeps more of each dollar of sales as profit, with a net margin of −2427% compared with −4646% at Yarrow Bioscience.
Yarrow Bioscience pays a dividend yielding 142%; Can-Fite BioPharma does not pay one.
Yarrow Bioscience scores higher on the StockData Score (11 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CANF | YARW |
|---|---|---|
| Size and price | ||
| Market cap | – | $37.9M |
| Share price | $1.53 | $14.21 |
| Change, 1 year | −79.3% | −24.1% |
| Change, 5 years | −99.4% | −98.5% |
| Beta (5Y) | 1.47 | 2.07 |
| Employees | 5 | 10 |
| StockData Score | ||
| Total score | 1 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | – | 66.6× |
| P/B | – | 1.7× |
| FCF yield | – | −87.3% |
| Fair value | – | $7.04 |
| Margin of safety | – | −102% |
| Growth | ||
| Revenue growth (TTM) | −39.9% | 13.8% (better) |
| Revenue growth, 5Y average | −11.9% (better) | −51.4% |
| Profitability | ||
| Operating margin | −2457% (better) | −5219% |
| Net margin | −2427% (better) | −4646% |
| FCF margin | −2210% (better) | −5811% |
| Return on equity | −217% | −86.9% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −35.0× | – |
| Current ratio | 3.60 | 15.26 (better) |
| Altman Z-score | – | −33.58 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 142% |
| Shareholder yield | – | 142% |
| Ownership | ||
| Held by institutions | 1.9% | 11.6% |
| Held by insiders | 0.00% | 82.1% |
| Short interest, % of float | – | 29.7% |
Go deeper
- CANF stock overview
- CANF income statement
- CANF valuation and score
- YARW stock overview
- YARW income statement
- YARW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.